ATC Index
Learn about Perindopril, an ACE inhibitor medication used to treat hypertension and heart failure. Discover dosage, side effects, and drug interactions.
Browse our catalog for available pharmaceutical products and competitive pricing.
Perindopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor belonging to the ATC classification C09, which encompasses agents acting on the renin-angiotensin system. It was developed in the 1980s and has become one of the most widely prescribed antihypertensive medications globally. Perindopril works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor hormone, thereby promoting vasodilation and reducing blood pressure.
This pharmaceutical compound is marketed under various brand names including Coversyl, Aceon, and others, depending on geographic location. Perindopril is available in oral tablet formulations with typical strengths ranging from 2 mg to 8 mg. It is commonly used as a monotherapy or in combination with other antihypertensive agents such as calcium channel blockers or diuretics. The drug has demonstrated excellent efficacy in clinical trials and is recommended by major cardiovascular societies for the management of hypertension and heart failure.
The pharmaceutical profile of Perindopril includes rapid absorption following oral administration, with peak plasma concentrations achieved within 1-2 hours. The drug undergoes hepatic metabolism and has an elimination half-life of approximately 3-10 hours, though its active metabolite perindoprilat has a much longer half-life, contributing to the drug's sustained therapeutic effects. This pharmacokinetic advantage allows for convenient once-daily dosing in most clinical scenarios.
Perindopril functions as a competitive inhibitor of angiotensin-converting enzyme (ACE), a zinc-dependent metalloproteinase responsible for the conversion of the inactive angiotensin I to the highly potent vasoconstrictor angiotensin II. By blocking this critical enzymatic step, Perindopril effectively reduces the formation of angiotensin II while simultaneously increasing circulating levels of angiotensin I and other vasodilatory kinins such as bradykinin. The net result is a significant decrease in systemic vascular resistance, reduced aldosterone secretion, and improved renal perfusion pressure.
Perindopril has been extensively studied and approved for multiple cardiovascular indications. Its therapeutic utility extends beyond simple blood pressure reduction to include cardioprotective and renoprotective effects, making it a valuable component of modern cardiovascular therapy regimens.
Perindopril dosing should be individualized based on patient factors including age, renal function, body weight, concurrent medications, and specific indication. Most patients achieve optimal blood pressure reduction at doses between 4-8 mg daily. Initial therapy typically begins at lower doses with gradual titration over 2-4 weeks to minimize adverse effects and optimize tolerability. Renal dose adjustments are necessary in patients with significant renal impairment (creatinine clearance <30 mL/min).
| Indication | Typical Dose | Frequency | Route |
|---|---|---|---|
| Hypertension (initial) | 2-4 mg | Once daily | Oral |
| Hypertension (maintenance) | 4-8 mg | Once daily | Oral |
| Heart failure | 2-4 mg initial, titrate to 4-8 mg | Once daily | Oral |
| Post-myocardial infarction | 2-4 mg initial, increase to 8 mg | Once daily | Oral |
Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Perindopril should be taken at the same time each day, preferably in the morning, with or without food. If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose; do not double dose.
Perindopril participates in several clinically significant drug interactions that require careful monitoring and potential dose adjustments. Healthcare providers must review all concurrent medications before initiating Perindopril therapy, as some combinations may be contraindicated.
Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Individual patient factors, comorbidities, and medication histories must be considered when determining appropriateness of Perindopril therapy.
Yes, Perindopril has an excellent long-term safety profile when used appropriately under medical supervision. Numerous large-scale clinical trials spanning 5-10 years have demonstrated sustained benefit and safety with continuous use. However, regular monitoring of blood pressure, renal function (serum creatinine and eGFR), and electrolytes (particularly potassium) is essential. Most patients tolerate Perindopril well chronically, though approximately 10-20% experience persistent dry cough which may necessitate switching to an alternative antihypertensive class.
Perindopril can be taken with or without food, though some evidence suggests that food consumption may slightly delay but not significantly reduce overall absorption. For consistency and adherence purposes, it is recommended to take Perindopril at the same time each day, preferably in the morning. Whether taken with breakfast or on an empty stomach is a matter of individual preference and tolerability. Some patients find taking it with food reduces gastric upset if that occurs.
If you miss a dose of Perindopril, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Never double-dose to make up for a missed dose, as this increases the risk of hypotension and adverse effects. If you frequently forget doses, consider using a pill organizer, setting phone reminders, or coordinating medication timing with daily activities such as breakfast to improve adherence.
Chat on WhatsApp